Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03CHM
|
|||
| Former ID |
DNCL002512
|
|||
| Drug Name |
MSC1936369B
|
|||
| Synonyms |
Pimasertib; 1236699-92-5; AS703026; AS-703026; Pimasertib (AS-703026); MSC1936369B; UNII-6ON9RK82AL; AS 703026; (S)-N-(2,3-dihydroxypropyl)-3-(2-fluoro-4-iodophenylamino)isonicotinamide; 6ON9RK82AL; N-[(2S)-2,3-Dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]-4-pyridinecarboxamide; 1204531-26-9; C15H15FIN3O3; N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodo-anilino)pyridine-4-carboxamide; N-((2S)-2,3-dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)pyridine-4-carboxamide; Pimasertib [USAN:INN]
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1], [2] | |
| Company |
EMD Serono
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H15FIN3O3
|
|||
| Canonical SMILES |
C1=CC(=C(C=C1I)F)NC2=C(C=CN=C2)C(=O)NCC(CO)O
|
|||
| InChI |
1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1
|
|||
| InChIKey |
VIUAUNHCRHHYNE-JTQLQIEISA-N
|
|||
| CAS Number |
CAS 1204531-26-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
85183024, 89947069, 99437175, 124757278, 125164082, 131480889, 135264540, 135267186, 136340134, 136367436, 136368089, 136920269, 137500464, 144115630, 152258364, 160647201, 160709020, 162037620, 162202575, 164041502, 164835959, 172232519, 174006376, 174526610, 176251505, 177749091, 186022480, 188899591, 198984263, 215785751, 223366201, 223382798, 223603881, 223704297, 228806461, 242058433, 242587784, 244900225, 249867996, 252076945, 252110021, 252444723, 252451745, 252543462
|
|||
| ChEBI ID |
CHEBI:94793
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7872). | |||
| REF 2 | Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer. 2013 Nov;133(9):2089-101. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.